Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
10.79
-0.15 (-1.37%)
Sep 8, 2026, 3:14 PM EDT - Market open
Sagimet Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
670.69M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 2.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 462.25M |
| MiMedx Group | 355.17M |
| Valneva SE | 163.30M |
| Gyre Therapeutics | 109.82M |
| Allogene Therapeutics | 4.64M |
| Prime Medicine | 4.07M |
| Shattuck Labs | 1.00M |
| Altimmune | 31.00K |
SGMT News
- 6 days ago - Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences - GlobeNewsWire
- 14 days ago - Sagimet Biosciences advances AURORA clinical trial - TheFly
- 14 days ago - Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026 - GlobeNewsWire
- 21 days ago - Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Sagimet Biosciences price target raised to $56 from $49 at Canaccord - TheFly
- 23 days ago - Sagimet Biosciences price target raised to $29 from $12 at Citizens - TheFly
- 26 days ago - Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients - GlobeNewsWire
- 4 weeks ago - Sagimet Biosciences Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts